论文部分内容阅读
异基因造血干细胞移植(allo HSCT)是治疗恶性血液病的有效手段。传统的清髓性allo HSCT采用最大限量的放化疗预处理方案,以期彻底根除肿瘤细胞和摧毁宿主的免疫系统,但伴随着与剂量相关的不良反应和死亡率明显增高[1]。近年来,以氟达拉滨为主的非清髓性预处理方案,应用了强烈、
Allogeneic hematopoietic stem cell transplantation (allo HSCT) is an effective treatment of hematologic malignancies. Traditional myeloablative allo HSCT uses a maximum amount of chemoradiation and chemotherapeutic regimens in order to eradicate tumor cells completely and destroy the host’s immune system, but associated with dose-related adverse reactions and mortality was significantly increased [1]. In recent years, fludarabine-based non-myeloablative preconditioning program, the application of a strong,